Comera Life Sciences

OTR Acquisition Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business Combination

Retrieved on: 
Friday, February 4, 2022
Professional Services, Health, Finance, Research, Science, Biotechnology, EST, Register, Forward-looking statement, Risk, Patient, U.S. Securities and Exchange Commission, Sale, Failure, Communication, OTR, SPAC, SEC, Proxy, Form, Technology, Adoption, Securities Act of 1933, Brickell Avenue, Person, Prospectus, Medicine, Freedom, Nasdaq, Reading, Acquisition, Suite, Registration statement, United States Army Acquisition Corps, Risk management, Security (finance), Ownership, Holding company, OTR Acquisition Corp., Comera Life Sciences, OTR ACQUISITION CORP., COMERA LIFE SCIENCES

OTR Acquisition Corp. (Nasdaq: OTRAU, OTRA and OTRAW), a publicly traded special purpose acquisition company (SPAC), today announced the confidential submission with the U.S. Securities and Exchange Commission (SEC) of a draft registration statement on Form S-4 (the Registration Statement) relating to its previously announced proposed business combination with Comera Life Sciences, Inc.

Key Points: 
  • OTR Acquisition Corp. (Nasdaq: OTRAU, OTRA and OTRAW), a publicly traded special purpose acquisition company (SPAC), today announced the confidential submission with the U.S. Securities and Exchange Commission (SEC) of a draft registration statement on Form S-4 (the Registration Statement) relating to its previously announced proposed business combination with Comera Life Sciences, Inc.
  • OTR is sponsored by OTR Acquisition Sponsor LLC, an affiliate of investor and entrepreneur Nicholas J.
  • In connection with the proposed business combination, Comera Life Sciences Holdings, Inc. (Holdco) will file the Registration Statement publicly which will include a proxy statement of OTR and a prospectus of Holdco.
  • Holdco and OTR will also file other documents regarding the proposed business combination with the SEC.

Comera Life Sciences to Become Publicly Traded via Business Combination with OTR Acquisition Corp.

Retrieved on: 
Monday, January 31, 2022
Research, Biotechnology, Other Health, Managed Care, Health, Pharmaceutical, Other Science, Science, Oncology, Growth, Risk, Biotechnology, Form, Market, Technology, Adoption, Brickell Avenue, Nasdaq, Compliance, Acquisition, Multimedia, U.S. Securities and Exchange Commission, Prospectus, 100,000, Quality of life, Research, Director, Leadership, View, Failure, SPAC, Person, Prognosis, Industry, EST, Safety, Forward-looking statement, Patient, OTR, SEC, Medicine, Freedom, LLP, Reading, Suite, Saudi Research and Marketing Group, Therapy, Pharmaceutical industry, Management, Security (finance), Risk management, Ownership, Holding company, Comera Life Sciences, OTR Acquisition Corp., COMERA LIFE SCIENCES, OTR ACQUISITION CORP.

Comera Life Sciences, Inc. (Comera or the Company), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, and OTR Acquisition Corp. (Nasdaq: OTRAU, OTRA and OTRAW) (collectively referred herein as OTR), a publicly traded special purpose acquisition company (SPAC), today announced they have entered into a business combination agreement.

Key Points: 
  • Comera Life Sciences, Inc. (Comera or the Company), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, and OTR Acquisition Corp. (Nasdaq: OTRAU, OTRA and OTRAW) (collectively referred herein as OTR), a publicly traded special purpose acquisition company (SPAC), today announced they have entered into a business combination agreement.
  • Maxim Group LLC served as sole financial and capital markets advisor to Comera in connection with the business combination agreement.
  • Comera and OTR will hold an investor call on Friday, Feb. 4 at 8:30 a.m. EST to discuss the business combination.
  • Neither Holdco, Comera nor OTR gives any assurance that either Comera or OTR will achieve its expectations.